Promising 5-year survival rates with pembrolizumab in advanced melanoma 

Five-year survival rates for patients with advanced melanoma treated with pembrolizumab (Keytruda) are 34%, according to the longest follow-up study to date. Results from the international KEYNOTE-001 study involving 655 patients also show an estimated five-year overall survival rate of 41% for treatment-naïve patients with the PD-1 inhibitor. Published in the Annals of Oncology, the ...

Already a member?

Login to keep reading.

© 2021 the limbic